Certainly. As you mentioned, I'm Anita Fineberg. I'm the chief privacy officer and corporate counsel of IMS Health for Canada and Latin America.
With me this morning is Gary Fabian, the company's vice-president, public affairs and government relations.
Also with me is Dr. Léo-Paul Landry, a member of our national medical advisory board and a past CEO and secretary general of the Canadian Medical Association. Dr. Landry brings the physician's perspective to the issue we'll discuss today and has particular experience and expertise in the province of Quebec.
I'd like to first thank the committee for providing IMS the opportunity to appear before you today. With the committee's permission, Gary will first provide you with some information on our IMS business, what we do, the data we collect, and our contribution to the advancement of health; and then I'll explain the impact that PIPEDA has had on our business and why we're here today.